Aequus Pharmaceuticals Inc., of Vancouver, British Columbia, completed dosing in the first stage of its phase I trial for the once-weekly transdermal aripiprazole patch, AQS1301. This study is the first in a two-stage phase I proof-of-concept program designed to assess the rate of absorption and to evaluate the profile of drug delivery over a seven-day period with Aequus’ transdermal formulation in 12 healthy volunteers. Results are expected to be announced early in 2016.